A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

Inclusion Criteria:

1. Subject voluntarily agrees to participate in this study and signs an InstitutionalReview Board -approved informed consent prior to performing any of the ScreeningVisit procedures.

2. Males and females at 18-75 years of age, inclusive, at the Screening Visit.

3. Have a clinical diagnosis of pancreatic cancer.

4. An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.

5. Expected survival time of≥6 months.

6. No serious hematologic and cardiac abnormalities of the liver, kidneys, orcoagulation functions.

Exclusion Criteria:

1. Prior treatment with other oncolytic virus or systemic therapy for pancreaticcancer.

2. Previous allogeneic hematopoietic stem cell transplantation or organtransplantation.

3. Immunocompromised patients.

4. Known alcohol or drug dependency.

5. Women who are pregnant or breastfeeding.